恒瑞医药：注射用SHR-1826、阿得贝利单抗注射液、贝伐珠单抗注射液获得药物临床试验批准通知书

Core Viewpoint - Heng Rui Medicine has received approval from the National Medical Products Administration for clinical trials of three injectable drugs, indicating progress in its oncology pipeline [1] Group 1: Clinical Trial Approvals - The company's subsidiaries, Suzhou Shengdiya Biopharmaceutical Co., Ltd. and Shanghai Shengdi Medicine Co., Ltd., have been granted clinical trial approval for SHR-1826, Adebali monoclonal antibody injection, and Bevacizumab injection [1] - SHR-1826 is an antibody-drug conjugate targeting c-MET, designed to selectively bind to tumor cell surface antigens and induce cell death [1] - Adebali monoclonal antibody injection, a humanized anti-PD-L1 monoclonal antibody, aims to block the PD-1/PD-L1 pathway, reactivating the immune system's anti-tumor activity [1] Group 2: Product Development and Market Status - Adebali monoclonal antibody injection (brand name: Ailili) was approved for market in March 2023 for first-line treatment of extensive-stage small cell lung cancer in combination with carboplatin and etoposide [1] - Bevacizumab, a humanized anti-VEGF monoclonal antibody, was co-developed by domestic and foreign pharmaceutical companies and has been marketed since 2004 in the U.S. under the brand name Avastin [1] - The company's Bevacizumab injection was approved for market in June 2021, with multiple formulations currently available in China and globally [1]